407318 | β-Interferon, Human, Recombinant, CHO Cells

407318
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      407318-10UG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service

          Plastic ampoule 10 μg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewRecombinant, human interferon-β (IFN-β) expressed in CHO cells as a single glycosylated polypeptide containing 166 amino acids. Purified by chromatographic methods. IFN-β is a type I cytokine produced in response to exposure to viruses or double-stranded RNAs. It is also induced by other cytokines, such as TNF and IL-1. It is involved in the regulation of non-specific humoral immune responses and immune responses to viral infections, and thus exhibits anti-viral, anti-proliferative, and immunomodulating properties. The biological activity of IFN-β, unlike IFN-α, is strictly species-specific and will not be active across species.
          Catalogue Number407318
          Brand Family Calbiochem®
          SynonymsInterferon α-2 precursor, IFN-β-1a, rHuIFN-β-1a
          References
          ReferencesGoebel, M.U., et al. 2005. Physiol. Behav. 84, 807.
          Graber, J., et al. 2005. J. Neuroimmunol. 161,169.
          Mallada-Frechin, J., et al. 2005. Rev. Neurol. 40, 482.
          Patten, S.B., et al. 2005. Mult. Scler. 11, 175.
          Pohl, D., et al. 2005. Neurology 64, 888.
          Schwid, S.R., et al. 2005. Arch. Neurol. 62, 785.
          Product Information
          FormLyophilized
          FormulationLyophilized from 62 mg/ml mannitol, 9.1 mg/ml human albumin, 0.9 mg/ml acetate, pH 7.0-7.2.
          Applications
          Biological Information
          Biological activityReported as IU/mg on a lot-specific basis using a viral resistance assay
          Purity≥98% by SDS-PAGE
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Blue Ice Only
          Toxicity Standard Handling
          Storage -20°C
          Protect from Moisture Protect from moisture
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, refrigerate (4°C) for short-term storage or aliquot and freeze (-20°C) for long-term storage. Stock solutions are stable for up to 7 days at 4°C or for up to 4 months at -20°C. Avoid freeze/thaw cycles of solutions.
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          407318

          References

          Reference overview
          Goebel, M.U., et al. 2005. Physiol. Behav. 84, 807.
          Graber, J., et al. 2005. J. Neuroimmunol. 161,169.
          Mallada-Frechin, J., et al. 2005. Rev. Neurol. 40, 482.
          Patten, S.B., et al. 2005. Mult. Scler. 11, 175.
          Pohl, D., et al. 2005. Neurology 64, 888.
          Schwid, S.R., et al. 2005. Arch. Neurol. 62, 785.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision14-May-2009 JSW
          SynonymsInterferon α-2 precursor, IFN-β-1a, rHuIFN-β-1a
          DescriptionRecombinant, human interferon-β (IFN-β) expressed in CHO cells as a single glycosylated polypeptide containing 166 amino acids. Purified by chromatographic methods. IFN-β is a type I cytokine produced in response to exposure to viruses or double-stranded RNAs. It is also induced by other cytokines, such as TNF and IL-1. It is involved in the regulation of non-specific humoral immune responses and immune responses to viral infections, and thus exhibits anti-viral, anti-proliferative, and immunomodulating properties. The biological activity of IFN-β, unlike IFN-α, is strictly species-specific and will not be active across species.
          FormLyophilized
          FormulationLyophilized from 62 mg/ml mannitol, 9.1 mg/ml human albumin, 0.9 mg/ml acetate, pH 7.0-7.2.
          Purity≥98% by SDS-PAGE
          Biological activityReported as IU/mg on a lot-specific basis using a viral resistance assay
          SolubilityReconstitute with sterile water to ≥100 µg/ml, containing 0.1% HSA or BSA. Further dilute with aqueous buffer just prior to use.
          Storage -20°C
          Protect from moisture
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, refrigerate (4°C) for short-term storage or aliquot and freeze (-20°C) for long-term storage. Stock solutions are stable for up to 7 days at 4°C or for up to 4 months at -20°C. Avoid freeze/thaw cycles of solutions.
          Toxicity Standard Handling
          ReferencesGoebel, M.U., et al. 2005. Physiol. Behav. 84, 807.
          Graber, J., et al. 2005. J. Neuroimmunol. 161,169.
          Mallada-Frechin, J., et al. 2005. Rev. Neurol. 40, 482.
          Patten, S.B., et al. 2005. Mult. Scler. 11, 175.
          Pohl, D., et al. 2005. Neurology 64, 888.
          Schwid, S.R., et al. 2005. Arch. Neurol. 62, 785.